Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Accumulated Expenses: 2013-2025

Historic Other Accumulated Expenses for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $7.1 million.

  • Coherus Oncology's Other Accumulated Expenses fell 51.10% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 51.10%. This contributed to the annual value of $20.0 million for FY2024, which is 162.56% up from last year.
  • Latest data reveals that Coherus Oncology reported Other Accumulated Expenses of $7.1 million as of Q3 2025, which was up 4.76% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Other Accumulated Expenses ranged from a high of $20.0 million in Q4 2024 and a low of $3.5 million during Q4 2021.
  • In the last 3 years, Coherus Oncology's Other Accumulated Expenses had a median value of $11.4 million in 2025 and averaged $12.0 million.
  • As far as peak fluctuations go, Coherus Oncology's Other Accumulated Expenses plummeted by 71.33% in 2021, and later surged by 204.52% in 2022.
  • Quarterly analysis of 5 years shows Coherus Oncology's Other Accumulated Expenses stood at $3.5 million in 2021, then skyrocketed by 204.52% to $10.6 million in 2022, then decreased by 28.27% to $7.6 million in 2023, then surged by 162.56% to $20.0 million in 2024, then tumbled by 51.10% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $6.8 million for Q2 2025, and $11.4 million during Q1 2025.